enGene (NASDAQ:ENGN) Shares Gap Down to $15.74

Shares of enGene Holdings Inc. (NASDAQ:ENGN) gapped down prior to trading on Thursday . The stock had previously closed at $15.74, but opened at $15.34. enGene shares last traded at $15.34, with a volume of 1,122 shares trading hands.

Analyst Ratings Changes

Several brokerages recently commented on ENGN. UBS Group began coverage on enGene in a report on Thursday, March 28th. They set a “buy” rating and a $37.00 target price on the stock. Guggenheim initiated coverage on shares of enGene in a research report on Monday. They set a “buy” rating and a $34.00 target price on the stock. Morgan Stanley began coverage on shares of enGene in a report on Friday, March 8th. They set an “overweight” rating and a $40.00 price target for the company. SVB Leerink assumed coverage on shares of enGene in a research note on Tuesday, February 20th. They set an “outperform” rating and a $31.00 price target on the stock. Finally, Leerink Partnrs reissued an “outperform” rating on shares of enGene in a research report on Tuesday, February 20th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $35.50.

enGene Stock Performance

The business’s fifty day simple moving average is $15.71.

Hedge Funds Weigh In On enGene

Large investors have recently modified their holdings of the stock. Citadel Advisors LLC bought a new stake in enGene in the fourth quarter valued at about $185,000. Goldman Sachs Group Inc. acquired a new position in shares of enGene in the 4th quarter worth approximately $346,000. Royal Bank of Canada bought a new stake in shares of enGene in the 4th quarter valued at approximately $349,000. Vivo Capital LLC acquired a new stake in shares of enGene during the 4th quarter valued at approximately $6,264,000. Finally, Omega Fund Management LLC bought a new position in enGene during the fourth quarter worth $10,441,000. Institutional investors own 64.16% of the company’s stock.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.